Polymyositis and dermatomyositis historical perspective

Polymyositis and dermatomyositis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polymyositis and dermatomyositis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polymyositis and dermatomyositis historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polymyositis and dermatomyositis historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polymyositis and dermatomyositis historical perspective
CDC on Polymyositis and dermatomyositis historical perspective
Polymyositis and dermatomyositis historical perspective in the news
Blogs on Polymyositis and dermatomyositis historical perspective
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Polymyositis and dermatomyositis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Historical Perspective

Discovery

• [Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].

• The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
• In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
• In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
• In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:
  • Primary idiopathic polymyositis (PM)
  • Primary idiopathic dermatomyositis (DM)
  • DM/PM associated with neoplasia
  • Childhood DM/PM associated with vasculitis
  • DM/PM with associated collagen-vascular disease
• In 1991, Dalakas
• By 1990, seven myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different cytoplasmic ribonucleoproteins including
  • Helicase protein (Mi2)
  • Signal recognition particle (SRP)
  • Anti-aminoacyl-tRNA synthetases such as
    • Histidyl (Jo1)
    • Threonyl (PL-7)
    • Alanyl (PL-12)
    • Glycyl (EJ)
    • Isoleucyl (OJ)
• In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA).

Landmark Events in the Development of Treatment Strategies

• In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].